Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: Correlation with ErbB2 and p66 Shc expression

Breast Cancer Research and Treatment

Volumn 49, Issue 2, 1998, Pages 119-128

  Stevenson, Lisa E ^a   Frackelton Jr , A Raymond ^b,c  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; EGFR; ErbB2; Phosphotyrosine; Shc; Signal transduction

Indexed keywords

PHOSPHOPROTEIN; PROTEIN; PROTEIN P52; PROTEIN P66; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; BREAST NEOPLASMS; FEMALE; HUMANS; PHOSPHORYLATION; PROTEINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0031812342     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006007227747     Document Type: Article

References (59)

1. Flick MB, Sapi E, Perrotta PL, Maher MG, Halaban R, Carter D, Kacinski BM: Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Oncogene 14: 2553-2561, 1997
2. Kacinski BM, Scata KA, Carter D, Lee LD, Sapi E, King BL, Chambers SK, Jones MA, Pirro MH, Stanley ER et al.: FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 6: 941-952, 1991
3. Luqmani YA, Graham M, Coombes RC: Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66: 273-280, 1992
4. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE: Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148: 225-232, 1996
5. Kannan S, De Santis M, Lohmeyer M et al.: Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 272: 3330-3335, 1997
6. Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev 16: 559-589, 1995
7. Hines SJ, Organ C, Kornstein MJ, Krystal GW: Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 6: 769-779, 1995
8. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di FP, Kraus MH: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821, 1995
9. Carraway KL, Cantley LC: A neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5-8, 1994
10. Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF: Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 14: 687-696, 1997
11. Earp HS, Dawson TL, Li X, Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132, 1995
12. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264, 1996
13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
14. Hynes N: Amplification and overexpression of the ErbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Sem Cancer Biol 4: 19-26, 1993
15. McGuire W, Tandon A, Allred D, Chamness G, Clark G: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006-1012, 1990
16. Bradbury J, Arno J, Edwards P: Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland. Oncogene 8: 1551-1558, 1993
17. Hudziak R, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci 84: 7159-7163, 1987
18. Guy C, Webster M, Schaller M, Parsons T, Cardiff R, Muller W: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci 89: 10578-10582, 1992
19. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci PG: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104, 1992
20. Segatto O, Pelicci G, Giuli S, Digiesi G, DiFiore PP, McGlade J, Pawson T, Pelicci PG: Shc products are substrates of erbB-2 kinase. Oncogene 8: 2105-2112, 1993
21. Janes PW, Daly RJ, deFazio A, Sutherland RL: Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9: 3601-3608, 1994
22. Xie Y, Pendergast AM, Hung MC: Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/ Neu. J Biol Chem 270: 30717-30724, 1995
23. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG et al.: Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360: 689-692, 1992
24. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation [see comments]. Nature 363: 45-51, 1993
25. Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, BarSagi D, Margolis B, Schlessinger J: Guanine-nucleotide releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363: 45-51, 1993
26. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG: Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. Embo J 16: 706-716, 1997
27. Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995
28. Blaikie P, Immanuel D, Wu J, Li N, Yajnik V, Margolis B: A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors. J Biol Chem 269: 32031-32034, 1994
29. Kavanaugh WM, Williams LT: An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 266: 1862-1865, 1994
30. Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J: Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14: 5192-5201, 1994
31. Van der Geer P, Pawson T: The PTB domain: a new protein module implicated in signal transduction. Trends Biochem Sci 20: 277-280, 1995
32. Bork P, Margolis B: A phosphotyrosine interaction domain. Cell 80: 693-694, 1995
33. Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, Pelicci PG: Formation of Shc-Grb2 complexes is necessary to induce neoplastic tranformation by overexpression of Shc proteins. Oncogene 9: 2827-2836, 1994
34. Ravichandran KS, Lorenz U, Shoelson SE, Burakoff SJ: Interaction of Shc with Grb2 regulates association of Grb2 with mSOS. Mol Cell Biol 15: 593-600, 1995
35. Clark S, Stern M, Horovitz H: C. elegans cell signalling gene Sem-5 encodes a protein with SH2 and SH3 domains. Nature 356: 593-600, 1992
36. Maignan S, Guilloteau JP, Fromage N, Arnoux B, Becquart J, Ducruix A: Crystal structure of the mammalian Grb2 adaptor. Science 268: 291-293, 1995
37. Buday L, Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor. Cell 73: 611-620, 1993
38. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr, Backer JM, Ullrich A, White MF et al.: The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12: 1929-1936, 1993
39. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D: The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1 [see comments]. Nature 363: 83-85, 1993
40. Sasaoka T, Langlois WJ, Leitner JW, Draznin B, Olefsky JM: The signaling pathway coupling epidermal growth factor receptors to activation of p21ras. J Biol Chem 269: 32621-32625, 1994
41. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF: Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148: 549-558, 1996
42. Kraus M, Fedi P, Starks V, Muraro R, Aaronson S: Demonstration of ligand-dependent signalling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci 90: 2900-2904, 1993
43. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI: The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109-2123, 1994
44. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994
45. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
46. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255-263, 1993
47. Watanabe T, Shintani A, Nakata M, Shing Y, Folkman J, Igarashi K, Sasada R: Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 269: 9966-9973, 1994
48. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB: Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res 54: 4703-4709, 1994
49. Xie Y, Li K, Hung MC: Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Oncogene 10: 2409-2413, 1995
50. Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci PG: Not all Shc's roads lead to Ras. Trends Biochem Sci 21: 257-261, 1996
51. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, Segatto O, Di Fiore PP, Pelicci PG: Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 11: 899-907, 1995
52. Levitzki A, Gazit A: Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788, 1995
53. Clark JW, Santos-Moore A, Stevenson LE, Frackelton AR Jr: Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the Ras signaling pathway. Int J Cancer 65: 186-191, 1996
54. DiGiovanna MP, Stern DF: Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/ erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 55: 1946-1955, 1995
55. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A: Heregulin-dependent regulation of HER2/neu oncogenic signalling by heterodimerization with HER3. EMBO J 14: 4267-4275, 1995
56. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292-1300, 1996
57. Souttou B, Hamelin R, Crepin M: FGF2 as an autocrine growth factor for immortal human breast epithelial cells. Cell Growth Differ 5: 615-623, 1994
58. Sivaraman V, Wang H, Nuovo G, Malbon C: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997
59. Daly RJ, Binder MD, Sutherland RL: Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 9: 2723-2727, 1994